New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma
Progress in the management of potentially operable PA remains limited, relying solely on strategies to optimize the sequence of complete treatment, based on modern multidrug chemotherapy (FOLFIRINOX, GemNabPaclitaxel) and surgical resection. The identification of risk criteria, such as the existence of systemic disease, is an important issue, currently referred to as "biological borderline disease." Few data, particularly from prospective studies, allow us to identify biomarkers other than CA19-9. Combining ctDNA with CA19-9 could be of interest to best define biological borderline situations in PA.
Authors
- Jean Pinson (ORCID: https://orcid.org/0000-0002-4165-4233)
- Lilian Schwarz (ORCID: https://orcid.org/0000-0001-6726-8755)
- Nasrin Sarafan‐Vasseur (ORCID: https://orcid.org/0000-0001-7709-1252)
- Jean‐Baptiste Bachet (ORCID: https://orcid.org/0000-0003-4337-286X)
- António Sá Cunha (ORCID: https://orcid.org/0000-0003-4015-5368)
- Ludivine Beaussire (ORCID: https://orcid.org/0000-0003-0214-3016)
- Frédéric Di Fiore (ORCID: https://orcid.org/0000-0001-5237-2971)
- Julie Henriques (ORCID: https://orcid.org/0000-0002-0674-0953)
- Dewi Vernerey
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Sorbonne Université (FR)
- Methodology and Quality of Life Unit in Oncology (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Normandie Université (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Paul-Brousse (FR)
- Université de Rouen Normandie (FR)
- Université de Franche-Comté (FR)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1097/sla.0000000000006468
- Citations
- 10
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.83